C2 Therapeutics raises $11.6M for esophageal ablation

C2 Therapeutics raised $11.6 million from 44 investors to help advance its Coldplay Focal Cryoballoon Ablation System to treat Barrett's esophagus. It has previously raised about $10 million since 2007, according to SEC filings. In May, the startup presented data for its handheld device that showed that 90% of treated patients in a 44-patient study had partial or complete regeneration from Barrett's to normal tissue. Barrett's esophagus is a result of chronic injury from gastroesophageal reflux disease. Over time, the normal esophageal lining is replaced with abnormal cells, putting patients at greater risk of cancer. More

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.